New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
17:36 EDTOGXIOncoGenex sees having enough funds for operations into Q315
From April 1 through the date of this Current Report on Form 8-K, OncoGenex Pharmaceuticals has offered and sold 809,214 shares of its common stock pursuant to its At-the-Market Issuance Sales Agreement with MLV & Co. LLC. These sales resulted in net proceeds to the company of approximately $2.9M. Prior to these sales, the company had not made any sales under this “at the market” equity offering program, and, as the date of this Current Report on Form 8-K, shares of the company’s common stock having an aggregate value of approximately $22M remained available for sale under this offering program. Based on the company’s current expectations and operating plans, and before giving effect to the receipt of net proceeds from its proposed offering of securities, the company believes that its cash, cash equivalents, short-term investments and receivables from its collaboration arrangement with Teva will be sufficient to fund its current planned operations into the third quarter of 2015.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:21 EDTOGXIOncoGenex Phase 2 Borealis-1 trial resulted in 50% reduction in risk of death
OncoGenex Pharmaceuticals announced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer. Overall trial results indicated that the addition of 600mg apatorsen to standard of care chemotherapy showed a 14% reduction in risk of death and a 17% reduction in progressive disease and death when compared to chemotherapy alone. Over one-third of the patients in the trial had lower performance status, as defined by a Karnofsky score of 80 percent or less. These patients derived the greatest benefit from 600mg apatorsen in combination with chemotherapy, resulting in a 50% reduction in risk of death compared to chemotherapy alone. Less benefit was observed in the 1000mg apatorsen arm due to increased adverse events leading to a higher rate of discontinuation of both apatorsen and chemotherapy. Apatorsen 600mg was well tolerated in combination with chemotherapy.
December 16, 2014
06:37 EDTOGXIOncoGenex completes patients enrolment for Rainier clinical trial
Subscribe for More Information
December 12, 2014
16:13 EDTOGXIBiotechnology Value Fund reports 6.43% passive stake in OncoGenex

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use